Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

May 14, 2020
|
staff reporter

NEW YORK – CareDx and Veracyte said on Thursday that they have signed an agreement to make CareDx the exclusive worldwide commercialization partner for solid organ transplant rejection tests on Veracyte's nCounter Flex Analysis diagnostic platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Trump Announces Departure From WHO

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

Also, Vacuums Are Just Scary

A study of Great Danes homes in on a genomic region linked to fearfulness.

Limited Early Spread

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

PLOS Papers on Indonesian Archipelago Populations, Hookworm Secretome, Carotid Plaque GWAS

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.

What's Popular?

In Business News

  1. Fluidigm Leads May GenomeWeb Index on Early Detection SARS-Cov-2 Blood Test Collaboration Details

  2. Fry Laboratories Plans COVID-19 NGS Diagnostic Kit Offering

    Premium

  3. Sema4 Forms Coronavirus Testing Alliance With Connecticut

  4. Progenity Files for IPO, Seeks to Raise up to $100M

  5. Cancer Genetics Q4 2019 Revenues Up 12 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.